It is important to note, however, that the level for PD-L1 positivity in this study using the SP263 assay was set at ≥25%, which is not a clinically validated cut-off for anti-PD-(L)1 therapies in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.